Ingevity CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
NGVT
Ingevity CORPIngevity Corporation finalized its strategic portfolio review in 2025, divesting its industrial specialties and CTO refinery businesses, while reporting a net loss of $167.1 million for the year, impacted by significant impairment charges and legal expenses.
NYSE
NGVT
Ingevity CORP10-K: Ingevity Reports Significant Loss in 2024, Announces Strategic Review and Portfolio Repositioning
Ingevity Corporation reports a net loss of $430.3 million for 2024, driven by a goodwill impairment charge and restructuring activities, while announcing a strategic review of its industrial specialties product line.
NYSE
NGVT
Ingevity CORPIngevity Corporation's 2023 annual report details a year of strategic repositioning, including a significant restructuring of its Performance Chemicals segment, alongside a review of its financial performance.